Literature DB >> 9201818

Angiotensin converting enzyme inhibitors in pregnancy.

J M Mastrobattista1.   

Abstract

Angiotensin converting enzyme (ACE) inhibitors are excellent antihypertensive agents and are becoming widely used as first-line therapy for chronic hypertension in women of reproductive age owing to their efficacy and few side effects. Reports of adverse fetal and neonatal effects from the use of ACE inhibitors in pregnancy in both animal and human studies prompted recommendations against their use in human pregnancy by several authors. This review discusses the mechanism of action of ACE inhibitors and the use of ACE inhibitors in pregnancy both in experimental animals and use in human pregnancy. ACE inhibitors used during pregnancy may have untoward effects on the fetus. Based on reports in the literature, one should avoid starting ACE inhibitors during pregnancy and discontinue them in current users if at all possible.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201818     DOI: 10.1016/s0146-0005(97)80055-9

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  8 in total

Review 1.  Drug-induced congenital defects: strategies to reduce the incidence.

Authors:  M De Santis; B Carducci; A F Cavaliere; L De Santis; G Straface; A Caruso
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Taking ACE inhibitors during pregnancy. Is it safe?

Authors:  Savithiri Ratnapalan; Gideon Koren
Journal:  Can Fam Physician       Date:  2002-06       Impact factor: 3.275

3.  Taking angiotensin-converting enzyme inhibitors during pregnancy: is it safe?

Authors:  Almundher Al-Maawali; Asnat Walfisch; Gideon Koren
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

4.  Prolonged exposure to angiotensin-converting enzyme inhibitors during pregnancy. Fetal toxicity could be reversible.

Authors:  A Shrim; H Berger; J Kingdom; A Hamoudi; P S Shah; G Koren
Journal:  Can Fam Physician       Date:  2005-10       Impact factor: 3.275

5.  Spectrum of use for the angiotensin-receptor blocking drugs.

Authors:  M E Fabiani; C I Johnston
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

6.  Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations.

Authors:  Alissa R Caton; Erin M Bell; Charlotte M Druschel; Martha M Werler; Angela E Lin; Marilyn L Browne; Louise-Anne McNutt; Paul A Romitti; Allen A Mitchell; Richard S Olney; Adolfo Correa
Journal:  Hypertension       Date:  2009-05-11       Impact factor: 10.190

Review 7.  Maternal Hypertension During Pregnancy and the Risk of Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis.

Authors:  Anushuya Ramakrishnan; Laura J Lee; Laura E Mitchell; A J Agopian
Journal:  Pediatr Cardiol       Date:  2015-05-08       Impact factor: 1.655

8.  Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats.

Authors:  Tae Hwan Kim; Min Gi Kim; Soyoung Shin; Yong-Ha Chi; Soo-Heui Paik; Joo-Han Lee; Sun Dong Yoo; Yu Seok Youn; Jürgen B Bulitta; Sang Hoon Joo; Seok Won Jeong; Kwon-Yeon Weon; Beom Soo Shin
Journal:  BMC Pharmacol Toxicol       Date:  2016-07-26       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.